December 7, 2016
Neovac’s Lupus vaccine on USFDA’s fast track
The U.S. Food and Drug Administration (FDA) has granted “Fast Track” status to French biopharmaceutical company Neovacs’s IFNalpha Kinoid in…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Miguel Sieler
November 7, 2016
Neovacs enroles first U.S. patient in its Phase IIb study of IFNalpha Kinoid in lupus.
Neovacs, a player in active immunotherapy for the treatment of autoimmune diseases, has enroled the first U.S. patient in its international Phase IIb clinical study of IFNalpha Kinoid in lupus.